PO Box 54 Kjelsås
NO-0411 OSLO
Norway
Phone:
+47 23 00 79 90
Telefax:
+47 23 00 79 91
How to find us
Contact us
About Algeta
Algeta is an oncology company developing treatments for bone metastases and disseminated tumor types. The lead product Alpharadin is targeting bone metastases which occur frequently in major cancers including hormone-refractory prostate cancer, breast, lung, kidney, thyroid and represent an area of high unmet medical need.
Algeta' s pipeline is built on world-leading, proprietary technology. Algeta is developing new, targeted cancer alpha-pharmaceuticals that harness the unique characteristics of alpha particle emitters which are potent, well tolerated and convenient to use.
In the phase II clinical trial program for bone metastases in hormone-refractory prostate cancer Alpharadin demonstrated an increase in overall patient survival, improved quality of life and a placebo-like safety profile and entered phase III in 2008. These highly promising clinical results in combination with Alpharadin's unique bone-targeting properties highlight the potential of this new generation of cancer therapeutic to be a first-choice treatment for bone metastases.
|
Alpharadin phase III trial
For further information including a video on the Alpharadin ALSYMPCA phase III trial, please press the logo above. |
Latest News
Algeta to present at Piper Jaffray Fourth Annual Europe Conference in London
Oslo, Norway, 19 June 2009 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that its President & CEO Andrew Kay will present a corporate overview at the forthcoming Piper Jaffray Annual Europe Conference on Tuesday 23 June at 10.00 BST in London, UK. A copy of the presentation will be available on the Company website www.algeta.comRead more..
New research highlights potential of novel alpha-pharmaceutical in targeting and killing breast cancer cells
Oslo, Norway, 17 June 2009 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces results of new research demonstrating that the alpha particle emitter thorium-227 (227Th) linked to the monoclonal antibody trastuzumab (Herceptin) selectively targets and kills breast cancer cells.The research, which was conducted by a team of scientists from the Norwegian Radium Hospital led by Dr. Jostein Dahle in collaboration with Algeta, was presented at the 56th annual Society for Nuclear Medicine 2009 meeting (Toronto, Canada; 13-17 June).
Read more..
Algeta demonstrates potential of alpha-emitter platform to generate new antibody therapeutics targeting breast cancer and lymphoma
Oslo, Norway, 9 June 2009 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that a series of scientific papers demonstrating the targeted and localized anticancer potential of the alpha-emitter thorium-227 (227Th) linked to trastuzumab (Herceptin) and to rituximab (Rituxan) will be presented at the forthcoming 56th annual Society for Nuclear Medicine 2009 meeting (Toronto, Canada; 13-17 June).These antibodies target tumors expressing the cell surface proteins HER-2 and CD20, which are present on certain breast cancer and lymphoma cells, respectively.
Read more..